• Natera entered a strategic partnership with Aveta Biomics to support AVTA 30-01, a global Phase 3 registrational trial of APG-157 in locally advanced head and neck cancer.
• The trial will use serial Signatera testing to track molecular residual disease and treatment response during therapy and follow-up.
• About 826 patients are planned across North America, Europe, Asia-Pacific, Australia; enrollment is expected to start in 2H 2026.
• Signatera will serve as a secondary endpoint, positioning the test as a potential tool for earlier recurrence detection than imaging alone.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260629746130) on June 29, 2026, and is solely responsible for the information contained therein.